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Abstract
The molecular mechanisms of action of a HIV protease inhibitor, ritonavir, on hepatic function were explored on a genomic scale using
microarrays comprising genes expressed in the liver of Sprague–Dawley rats (Rattus norvegicus). Analyses of hepatic transcriptional fingerprints led
to the identification of several key cellular pathways affected by ritonavir treatment. These effects were compared to a compendium of gene
expression responses for 52 unrelated compounds and to other protease inhibitors, including atazanavir and two experimental compounds. We
identified genes involved in cholesterol and fatty acid biosynthesis, as well as genes involved in fatty acid and cholesterol breakdown, whose
expressions were regulated in opposite manners by ritonavir and bezafibrate, a hypolipidemic agonist of the peroxisome proliferator-activated
receptor α. Ritonavir also upregulated multiple proteasomal subunit transcripts as well as genes involved in ubiquitination, consistent with its known
inhibitory effect on proteasomal activity. We also tested three other protease inhibitors in addition to ritonavir. Atazanavir did not impact ubiquitin or
proteasomal gene expression, although the two other experimental protease inhibitors impacted both proteasomal gene expression and sterol
regulatory element-binding protein-activated genes, similar to ritonavir. Identification of key metabolic pathways that are affected by ritonavir and
other protease inhibitors will enable us to understand better the downstream effects of protease inhibitors, thus leading to better drug design and an
effective method to mitigate the side effects of this important class of HIV therapeutics.
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a global epidemic. As summarized in the 2006 UNAIDS report
(http://www.unaids.org/en/HIV_data/2006GlobalReport/
default.asp), an estimated 38.6 million people are living with
HIV worldwide. Though the epidemic continues, the manage-
ment of HIV and AIDS has improved considerably in recent
years, due in large part to the treatment advances in combating
HIV with combination therapy consisting of HIV reverse
transcriptase inhibitors (RTIs) and HIV protease inhibitors (PIs).⁎ Corresponding authors.
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doi:10.1016/j.ygeno.2007.06.004One of the first commercially available PIs for the treatment
of HIV was ritonavir (RTV) [1], and there are now several ad-
ditional PIs in the HIV treatment arsenal, including amprenavir,
indinavir, nelfinavir, saquinavir, lopinavir, and atazanavir
(ATZ). The HIV PIs, used together with RTIs in HAART
(highly active antiretroviral therapy), have been very effective
in lowering HIV viral loads [2–4]. However, because the ef-
fectiveness of antiretroviral therapy increases the successful
management of HIV infection and improves longevity, drug
side effects and toxicity have become of increasing concern [5].
Studies have shown that RTV, even in low-dose mono-
therapy, can affect serum lipid levels [6]. Patients treated with
RTV or other PIs (often metabolically boosted with RTV) can
develop hypercholesterolemia and hypertriglyceridemia, an
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HAART that develop hyperlipidemia are put on cholesterol-
lowering drugs such as statins or fibrates, the molecular mech-
anism(s) by which PIs contribute to hyperlipidemia is still being
investigated. The mechanistic contribution of HI. PIs to
hyperlipidemia is complicated by an association of this effect
with HIV infection alone [12] and the potential influence of
genetic predispositions [13], even though RTV does induce
hyperlipidemia in healthy volunteers [6]. Due to the ever-in-
creasing rate of infection and use of anti-HIV therapies, it is
important to get as good an understanding as possible of the
molecular mechanisms behind the hyperlipidemia effect,
leading to improved screening methods for drugs with the
fewest side effects for hyperlipidemia.
There is now considerable evidence that some of the PI
effects on lipids are due to the inhibition of the 20S subunit of
the proteasome [14,15]. Researchers have shown that this
affects the levels of active sterol regulatory element binding
proteins (SREBPs) in both the liver and adipocytes [16,17].
SREBPs are transcription factors that regulate gene expression
of both cholesterol and fatty acid synthesis genes [18,19]. The
impact of proteasome function would predictably affect the
levels of many other proteins that are turned over in the
proteasome. For example, in mice treated with RTVon a high-
fat diet, ApoB levels were markedly increased [20]. ApoB
protein is turned over in the proteasome via the proteasome–
ubiquitin pathway [21,22]. Researchers have also shown that
RTV impacts adipocyte differentiation by monitoring changes
in gene expression of key adipogenic genes such as adiponectin
[23,24].
In addition to effects on serum lipids, RTV is known to
produce effects on the clinically important cytochrome P450
enzymes, notably its impact on CYP3A4 activity. RTV treatment
also gives rise to Pregnane X Receptor-mediated induction of
other cytochrome P450 genes responsible for the metabolism of
many drugs in humans and rats [25–27]. Since RTV both
induces and inhibits CYP3A4 [28], in addition to being a
substrate, preclinical and clinical pharmacokinetic behaviors are
complicated.
To date, most studies describe monitoring only sets of
predetermined genes. Here we describe an unbiased approach, in
which the effects of RTV on thousands of genes are monitored
simultaneously using microarrays in a common preclinical
model, the rat. We also compared RTV to a compendium of 52
other unrelated compounds with known toxicities [29]. Last, we
compared the gene expression profiles of ATZ and two
experimental PIs with that of RTV.
With this approach, we found that RTV may affect the
proteasome by impacting the expression of many genes en-
coding proteasomal subunits as well as genes in the ubiquitina-
tion pathway. We also found that part of RTV's molecular
fingerprint was a “mirror image” of that of the hypolipidemic
drug, bezafibrate. In addition, we used gene expression profiling
to discern important relationships between RTV's PXR-
mediated effects on drug metabolism and pharmacokinetics
and its effects on lipid metabolism. While RTV's overall
ubiquitin–proteasome, lipid, and PXR-related gene signatureswere also present in ATZ and the two experimental compounds,
RTV is still statistically differentiated from ATZ and the two
experimental compounds. Interestingly, ATZ is the only protease
inhibitor among those tested that did not induce the expression of
genes encoding the proteasomal subunit, while it did induce the
cholesterol and fatty acid biosynthesis genes. By taking an
unbiased approach of monitoring tens of thousands of genes, we
were able to dissect further the molecular mechanisms by which
hyperlipidemia may be occurring. This will help us to under-
stand better how the side effects can be overcome to aid in the
design of new inhibitors in the preclinical setting, in which
compounds are initially screened before going into humans.
Results
A compendium approach to gene expression profiling studies
on RTV
Using a custom 25K-probe DNA microarray enriched in rat
sequences expressed in the liver, we monitored the gene ex-
pression profile of RTV by comparing it to a liver gene
expression compendium of 52 unrelated compounds. Com-
pounds that were used to generate the liver toxicity
compendium included a variety of drugs and model hepatotox-
ins [29]. Together with 52 other compounds, we monitored the
overall transcriptional activity of RTV over three different
doses and treatment duration of 3 or 7 days. We showed that
RTV elicited a robust signature with several groups of genes
showing regulation in a dose-dependent manner (Fig. 1A).
These included genes encoding proteasomal subunits, genes
involved in β-oxidation, and cholesterol metabolism genes. In
subsequent sections, we also describe the characteristics of the
RTV gene signature relative to the other compounds in the
compendium.
Impact on PXR by RTV
Since RTV induces, inhibits, and is metabolized by the
hallmark PXR-responsive cytochrome P450 isoform, CYP3A4
in humans, and is a potent inhibitor of this enzyme, we investi-
gated the impact of RTVon rat homologues of cytochrome P450
genes that may be regulated by the xenobiotic receptor PXR.
Consistent with PXR-mediated induction, Fig. 1B shows a PXR-
responsive rat orthologue Cyp3a1 [30,31] (NM_013105, Entrez
25642, also known as Cyp3a3 and as Cyp3a23) that was
substantially upregulated in a dose-dependent fashion. The
upregulation of Cyp3a was confirmed by Western blot using
antibodies that recognize the family of Cyp3a (Fig. 1D). RTV
also upregulated other cytochrome P450 genes such as the
phenobarbital-inducible Cyp2b and cytochrome P450 genes
involved in cholesterol synthesis and metabolism, consistent
with observations of cross talk between the nuclear receptors
CAR, PXR, and other nuclear receptors [32,33]. Lanosterol 14-
α-demethylase (CYP51) was upregulated in RTV-treated rats.
Cytochrome P450s Cyp7a1 and Cyp8b1, both involved in bile
acid metabolism, were downregulated. In addition, Cyp1a1 and
Cyp1a2, both AhR-responsive genes that are induced by 3-
Fig. 1. (A) Heat map of expression changes in one-dimensional clustering of 2410 signature genes in RTV-treated rats with three different dosing regimens, together
with vehicle controls. Signature genes were defined as those with threefold or more change in expression ratio and p value less than 0.001 in at least three experiments.
Genes that are upregulated are shown in red and downregulated in green. Black denotes genes with no significant expression change. (B) Logarithmic expression ratios
for a set of cytochrome P450 genes in all RTV-treated rats together with vehicle controls. (C) Similar to (B) for a set of proteasomal and ubiquitin-related genes with
upregulation. Color scales are shown universally for (A), (B), and (C). Dynamic range of color scale is between log −0.3 and log 0.3. (D) Western blot using antibodies
that recognize the family of CYP3A confirms the upregulation of CYP3A.
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Cyp1a2 was downregulated in RTV-treated rats, whereas the
expression of the AhR bellwether gene, Cyp1a1, was not
affected (Fig. 1D). It is interesting to note that fibrate-inducible
Cyp4b1 and Cyp4a3 were downregulated in response to
RTV treatment. The significance of this finding will be discussed
later.RTV affects proteasomal and ubiquitination pathway gene
expression
Genes encoding various proteasomal subunits contributed to
the uniqueness of the RTV signature, as determined unbiasedly
by principal component analysis (PCA) of the RTV signature
within the context of a 52-compound compendium of gene
467P.Y. Lum et al. / Genomics 90 (2007) 464–473expression profiles. PCA established that the two high doses of
RTV administered to rats for 3 days elicited transcriptional
profiles that were unique to RTV's profile (see Supplemental
Fig. S1). A total of 790 sequences contributed to RTV's distinct
signature. Among the genes that contributed significantly to the
PCA were transcripts encoding proteasomal subunits or that
were annotated as having homology to proteasomal genes. The
transcriptional profiles of all proteasomal-related sequences that
contributed to the loading of the principal component analysis
are shown in Fig. 1C. Transcripts that were impacted include
those with homology to the human 26S proteasome-associated
pad1 homologue, proteasome subunit, α type 1 and β type 3,
proteasome 26S subunit, ATPase 2, and others (see supplemental
data for complete list). The upregulation of the various
proteasomal subunits was dose dependent. Since RTV is now
known to also inhibit eukaryotic proteasomal function [34], it is
likely that the transcriptional effects on proteasomal components
is a feedback response to this inhibition [35]. The expression
levels of some sequences related to the ubiquitination pathway
were also upregulated.
RTV affects expression of β -oxidation and fatty acid and
cholesterol biosynthesis genes
Bezafibrate is a member of the fibrate class of hypolipidemic
drugs that signal through the peroxisome proliferator-activated
receptor α (PPARα) to upregulate fatty acid β-oxidation. Since
RTV is known to produce the opposite lipid effect in patients, it
was of interest to compare the gene expression profiles of RTV
and bezafibrate to determine potential differences in effects on
cellular pathways. Clinical chemistry data from rats treated with
RTV showed that serum cholesterol concentrations were mildly
elevated in all rats dosed at 500 mg/kg/day for 3 days. At 7 days,
rats fed with 50 and 175 mg/kg/day also showed elevated
cholesterol levels. Earlier studies showed that rats showed
increased cholesterol levels even at 25 mg/kg/day when they
were administered RTV over longer periods of time (data not
shown). Mildly increased serum triglyceride levels were also
observed in some of the rats given higher doses of RTV. When
the transcriptional response of RTV was compared with that of
bezafibrate, we observed that many genes involved in fatty acid
and cholesterol metabolism were oppositely regulated by the
two compounds (Fig. 2). Using a simple t test to identify genes
that are significantly oppositely regulated in RTV- and
bezafibrate-dosed animals, we found that the fibrate hallmark
genes, such as genes encoding enzymes involved inβ-oxidation,
such as acetyl-CoA acyltransferase, peroxisomal enoyl-CoA:
hydrotase-3-hydroxyacyl-CoA bifunctional enzyme, carnitine
octanoyltransferase, and acyl CoA oxidase, were among the
most significantly affected. Transporters of the peroxisomal
membrane, such as the ATP-binding cassette half-transporters
and carnitine octanoyltransferase, were also upregulated after
bezafibrate but downregulated after RTV administration. Fatty
acid synthase was also oppositely regulated by the two com-
pounds. Genes encoding proteins involved in cholesterol bio-
synthesis and breakdown, such as Cyp51 and NADH-
cytochrome b5 reductase, and ESTs with homology to lanosterolsynthase, 7-dehydrocholesterol reductase, and acetyl-CoA syn-
thetase also showed significant opposite regulation between
RTV and bezafibrate. Another set of oppositely regulated
PPARα-inducible genes are Cyp4b1 and Cyp4a3. In addition,
RXR, which forms an obligate heterodimer with PPARα, was
also significantly downregulated at a level of threefold with a p
value b0.01 in RTV-treated rats. Interestingly, ESTs with
homology to mouse Angptl4 (PPARγ angiopoietin-related
protein) and Adfp (adipose differentiation related protein),
both known PPARγ-inducible proteins, were also oppositely
regulated between RTV and bezafibrate, consistent with
previous findings of RTV's effect on adipogenesis. Many of
the above-mentioned genes are also SREBP-regulated genes,
such as the cholesterol biosynthetic genes and FASN (fatty acid
synthase) (see supplemental data for complete list).
Do differences in gene expression signatures caused by other
PIs help explain lipid-related side effects?
To follow up on the results from the first study, we conducted
another set of experiments in rats to compare hepatic gene
expression profiles of two experimental HIV PIs (Merck A and
Merck B), RTV, and ATZ. We wanted to see if the gene
expression signatures brought on by these different PIs could
further help dissect the pathways that impact lipid levels. ATZ is
generally considered to have minimal hyperlipidemia-related
side effects; hence it was included in the study [36,37]. Detailed
pharmacokinetic analyses for this study were performed to help
us better interpret the gene expression signatures (Table 1).
We found that Cmax for all compounds and doses tested were
between 4 and 20 μM, indicating that compound exposure was
achieved (Table 1). However, for both doses of Merck A and
Merck B and for the ATZ low dose, marked differences in
AUC0–∞ were observed in the replicated (N=2) pharmacoki-
netic satellite animals. This may indicate that individual animals
in the N=5 expression profiling study cohort have variable drug
exposure. After normalization of AUC to a uniform 100 mg/kg/
day dose, we found that RTVexposure was 5- to 10-fold higher
than that of the other three compounds. RTV is both an inducer
and an inhibitor of the cytochrome P450 enzymes responsible
for its metabolism [28], so the difference in AUC across
compoundsmay be related to low absorption and/or metabolism.
Accordingly, average exposures showed low-dose RTV to be
most comparable to the high dose of the other three compounds.
Principal component analysis of a 505-gene signature set
obtained from one-way ANOVA showed that RTV is still
differentiated from the other PIs via its hepatic gene expression
fingerprint in this second study (see Supplemental Fig. S2). We
then performed a more focused pathway analysis around the
genes that we found to be impacted by RTV in the first study. We
found that all the compounds tested showed very similar patterns
with respect to SREBP-related genes, PXR-responsive genes, and
the mainstream Absorption, Distribution, Metabolism, and
Excretion-related genes (Fig. 3). In contrast, ATZ is the only
protease inhibitor among those tested that did not induce the
expression of genes encoding the proteasomal subunits (Fig. 3).
Genes involved in the ubiquitin degradation pathway were also
Fig. 2. Color display of logarithmic gene expression ratios for a set of gene that are significantly oppositely regulated in RTV- and bezafibrate-treated rats. This set of
genes was selected based on the t value as described in the text. The color scheme is as in Fig. 1. Dynamic range of color scale is between log −0.3 and log 0.3.
Experimental conditions are labeled.
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PIs. BecauseATZhas little effect on plasma lipid levels in human,
this particular proteasomal molecular fingerprint may represent
the differences between ATZ and the other PIs in this regard.
Discussion
A working model for RTV-induced hyperlipidemia in rats
As depicted in the cellular response model in Fig. 4, we
propose that RTV exerts its hyperlipidemia effects by a com-
bination of several pathways, interfering with the degradation of
key proteins via proteasomal function and antagonism of the
PPARα signaling pathway. A variety of genes in SREBP and
lipid pathways showed gene expression changes that areconsistent with this model, and PXR-related changes in the
cytochrome P450 class (such as Cyp7a1, 8b, and 51) may be
compensating for lipid dysregulation or perturbations of bile
acid homeostasis [38]. A comparison of the gene expression
profiles of RTV to the hypolipidemic drug bezafibrate shows
RTV to be a functional antagonist of PPARα in rats. Based on
our results, one of the affected pathways was PPARα-induced
fatty acid β-oxidation. Genes involved in fatty acid oxidation
were downregulated in RTV-treated rats. The gene expression
pattern of RTV was almost a mirror image of the expression
pattern of bezafibrate. Moreover, the expression of RXR, which
forms an obligate heterodimer with PPARα, was also signifi-
cantly downregulated at a level of threefold and p value b0.01 in
RTV-treated rats. Thus, one possibility is that RTV is an
antagonist to the PPARα signaling pathway, producing an
Table 1
Pharmacokinetic analysis summary for rats in study 2
Compound Dose
(mg/kg/day)
Animal AUC (0–∞)
(μM · h)
AUC average
(0–∞) (μM · h)
Cmax
(μM)
AUC normalized to
100 mg/kg/day (μM · h)
Average normalized
AUC (μM · h)
Atazanavir 300 1 29.1 72 8.3 10 18
Atazanavir 300 2 115.2 12.0 38
Atazanavir 600 3 69.0 71 16.2 12
Atazanavir 600 4 72.8 12.8 12
Merck A 100 1 34.4 26 9.7 34 22
Merck A 100 2 17.4 9.4 17
Merck A 500 3 122.8 86 8.3 25
Merck A 500 4 49.6 8.8 10
Merck B 160 1 38.0 21 19.8 24 10
Merck B 160 2 4.1 3.9 3
Merck B 800 3 83.7 55 11.5 10
Merck B 800 4 27.1 9.9 3
Ritonavir 50 1 64.4 51 4.8 129 104
Ritonavir 50 2 38.4 6.0 77
Ritonavir 170 3 197.0 180 16.8 116
Ritonavir 170 4 162.4 16.3 96
Drug concentrations in female Sprague–Dawley rat plasma were determined by LC–MS/MS following the last of three once-daily oral doses (N=2/dose/compound).
Noncompartmental analysis was used to derive area under the concentration–time curve (AUC) and the maximum plasma concentration (Cmax) and average results
were calculated. AUC was normalized to a dose of 100 mg/kg/day to compare relative exposure across compounds.
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triglyceride synthesis. Patients on HAART that experience
hyperlipidemic side effects are treated with fibrates, includingFig. 3. Heat map of the four groups of genes for atazanavir, RTV, Merck A, and Merck
ADME, ADME genes; Proteasomal, genes encoding proteasomal subunits and ubiqbezafibrate [39] to control triglycerides and statins to control
cholesterol. Our results, derived from gene expression studies in
rat liver, provide a mechanism for the effectiveness of thisB compounds. SREBP, SREBP-responsive genes; PXR, PXR-responsive genes;
uitin pathway. Dynamic range of color scale is between log −0.3 and log 0.3.
Fig. 4. A schematic diagram that illustrates a working hypothesis of RTV's molecular mechanisms of action in the cell. Pathways that are affected as determined by
gene expression analysis are depicted. Metabolic impairment by RTV could due to functionally antagonizing PPARα-responsive pathways or proteasomal inhibition,
resulting in dysregulation of SREBP levels. However, these pathways could be impacted independently, as discussed in the text.
470 P.Y. Lum et al. / Genomics 90 (2007) 464–473empirically derived cotherapy for PI-related hyperlipidemia.
However, even though we now have a better handle on the
overall impact of ritonavir on pathways as schematically
depicted in the working hypothesis, it is still unclear exactly
how these genes respond to RTV treatment. Further studies will
be needed to dissect direct effects of RTVon transcription versus
indirect effects via the proteasomes or PXR interplay. There is
also cross talk between transcription factors such as NF-κB and
AP-1 with PPARα; hence it is likely that several pathways that
could impact fatty acid and cholesterol biosyntheses and RTV
could impact one or several of them at different levels [40].
Future experiments will be needed to dissect these various
possibilities at a deeper level. In addition, though RTV induces
hyperlipidemia even in healthy volunteers, some of the
mechanistic contribution of HIV PIs to hyperlipidemia could
be complicated by an association of this effect with HIV
infection alone [12] and the potential influence of genetic
predispositions [13], as mentioned in the introduction. HIV
rodent models [41,42] might help to investigate this aspect
further.
Design of new PIs with limited hyperlipidemia liabilities
Monitoring the changes in expression of tens of thousands of
DNA sequences in rat produced by different PIs has provided us
with some distinct gene signatures to investigate further. Inaddition, our compendium of gene expression profiles showed
how hypolipidemic drugs, such as bezafibrate, may ameliorate
these side effects. Further, we tested this by conducting a
pharmacokinetically guided comparison of RTV with three
other PIs and evaluated effects on expression of PXR-related
genes, SREBP-related genes, proteasomal subunit genes, and
genes involved in fatty acid metabolism.
Among the other three PIs tested, gene expression patterns
were generally similar to that of RTV except for ATZ, which
differed from the rest of the PIs by the lack of upregulation of
genes encoding the proteasomal subunits. Paradoxically, ATZ
resembled the other PIs in gene responses related to SREBP
response. While this is puzzling, it is plausible that ATZ has
sufficient, albeit weak, proteasomal inhibitory activity to affect
immediate SREBP degradation (with subclinical effects on
cholesterol biosynthesis), but is not sufficient to trigger a
compensatory increase in proteasomal gene expression or
clinically significant change in lipid levels. But the impact on
the proteasomal function, weak as it may be, may have already
affected the gene expression of SREBP-activated genes because
of the more direct effect of SREBP on gene expression. From
Figs. 1C and 2, we observe that the SREBP-responsive genes
were already upregulated at 3 days (50 mg/kg), while the
proteasomal genes were not significantly upregulated until day
7 (50 mg/kg). The alternative explanation for this is that the
proteasomal fingerprint and the SREBP fingerprint can be
471P.Y. Lum et al. / Genomics 90 (2007) 464–473independent and can each affect lipid levels to different degrees.
Recently, the ubiquitin–proteasome system has been implicated
in the stability of diabetic atherosclerotic plaques [43,44]. In
mice treated with RTVon a high-fat diet, ApoB levels were also
markedly increased [20], most likely through impeded turnover
via the proteasome–ubiquitin pathway [21,22]. All this suggests
that the ubiquitin–proteasome system could impact the lipid
profile independently, playing a larger than expected role in
hyperlipidemia and other related symptoms in a SREBP-
independent manner. One of the ways to address this in the
future is by testing various proteasomal inhibitors across a range
of concentrations and monitoring the dynamics of the
proteasomal genes with respect to the lipid biosynthesis genes.
We have uncovered gene expression patterns across multiple
protease inhibitors and have begun to test more directly some of
the specific hypotheses. In addition, based on the comparison of
gene expression patterns alone for the PIs that we tested, we do
not see the two experimental PIs as having an advantage over
RTV with respect to the impact they have on both SREBP and
proteasomal signatures. ATZ, a PI with limited lipid liability in
humans, on the other hand, lacked the proteasomal signature.
Practically speaking, a method of screening one could employ
now in the preclinical setting, even without understanding the
complete molecular mechanism of action, would be to utilize the
more robust proteasomal signature as a filter to exclude
compounds that might bring on lipid effects. This can be
translated to a TaqMan assay in which key proteasomal and
ubiquitination pathway genes are monitored in rats to help guide
selection of future PIs.Materials and methods
Materials
All solvents were reagent grade and obtained from routine commercial
sources.
Animal studies
Two studies were conducted. In study 1, gene expression profiling and
comparison to a compendium of profiles were done as described in Waring et al.
[29]. Briefly, an oral dose regimen of 50, 175, or 500 mg/kg/day of RTV was
given to male Sprague–Dawley rats over a period of 3 or 7 days. Tissues were
collected 18 h after the last dose.
Study 2 compared gene expression profiles of four PIs. The study was based
on current International Conference on Harmonisation Harmonised Tripartite
Guidelines [46]. Animal care was in compliance with the USDAAnimalWelfare
Act (9 CFRParts 1, 2, and 3) and ILAR guidelines [47]. Briefly, female Sprague–
Dawley rats (age 9–10 weeks, CD (Crl: CD (SD)IGS BR)), seven animals/
compound) were treated once daily for 3 days with two Merck PI candidate
compounds and two marketed PIs, RTV and ATZ, at the following dose levels:
RTV, 50 and 170 mg/kg/day; ATZ, 300 and 600 mg/kg/day; Merck A, 160 and
800 mg/kg/day; Merck B, 100 and 500 mg/kg/day. At 24 h after the last dose,
livers were collected from five animals and RNA samples were prepared from the
liver. In the other two animals, blood was collected by orbital sinus bleed at 0,
0.25, 0.5, 1, 2, 4, 6, 8, 12, and 24 h after the last dose. Plasma was isolated and
LC–MS/MS determination of plasma concentrations and pharmacokinetic
analysis was done. Control rats (N=5) for the vehicle (10 ml/kg of 5%
ethanol:95% propylene glycol containing 2 eq of p-toluene sulfonic acid) were
treated identically. This study was carried out in female rats as opposed to male
rats as in the first study to look for common effects that are sex independent.Preparation of labeled cRNA and microarray hybridization
In study 1, DNase-treated rat liver total RNAs were isolated in Trizol and
processed essentially as described in [45] on Agilent 25 k rat chips v1.0 (GEO
Platform Series GPL4772). In study 2, after sample quality control (QC)
procedures, RNA samples were amplified, labeled, and hybridized with Fluor
reversal on Agilent 50k rat chips v2.1 (GEO Platform Series GPL3631) at the
Rosetta Gene Expression Laboratory according to general methods developed in
Hughes et al. [45] All compound-treated samples (N=5/group) were profiled
against a common reference pool made of all control samples.
Pharmacokinetic analysis
HIV protease inhibitor analytes were isolated from EDTA-treated rat plasma
by protein precipitation and quantified by LC–MS/MS in the positive ionization
mode. Analysis was done on a Sciex API 3000 mass spectrometer interfaced via
the Sciex heated nebulizer to a Micro-Aria LX4 LC system consisting of a HTS
Twin PAL CTC autosampler and Rheos pumps. Chromatography was on a
Waters Atlantis-C18, 2.1×50 mm (5 μm) column with a mobile-phase gradient
at flow rate 0.5 ml/min; A, acetonitrile containing 0.1% formic acid (w/v); B,
water containing 0.1% formic acid (w/v); gradient (time (min)/% B), 0.0/100;
0.5/100; 2.5/5; 3.0/5; 3.1/100; 5.0/100. LC–MS conditions were nebulization
gas, nitrogen at setting 8; auxiliary gas, nitrogen at 1 L/min; heater, 450 °C;
discharge current, 3; curtain gas, nitrogen at setting 12; collision gas, nitrogen at
setting 4. LC–MS analysis parameters were for Merck B, standard curve range
20–10,000 ng/ml, LOQ 20 ng/ml, precursor→product 781.5→217.1; Merck
A, standard curve range 5–10,000, LOQ (ng/ml) 5, precursor→product
756.4→192.0; RTV, standard curve range 10–10,000, LOQ (ng/ml) 10,
precursor→product 721.6→268.1; ATZ, standard curve range 5–10,000, LOQ
(ng/ml) 5, precursor→product 705.4→168.0; Crixivan (internal std), pre-
cursor→product 614.5→421.2, run acceptance criteria, 2/3 of the QCs within
20% CV and 25% of theoretical value.
Data analysis
After standard raw data processing, measured values of log(ratio) for each gene
from each treated animal were reported together with log(ratio) error, p value for
the significance of regulation relative to the control, and other quality control
metrics. All profiles passed spike-in based data QC and other QC metrics. In
addition to expression data, overviews such as one-dimensional clustering and two-
dimensional clustering and one-way ANOVAwere used to identify a set of genes
that discriminates among nine ANOVA groups (two doses for each of four
compounds and one control group). Prior to the ANOVA, a preselection criterion
required that a genewas significantly regulated based on a p valueb0.01,wasmore
than twofold changed in at least two compound-treated animals, and was regulated
at pb0.01 in fewer than two vehicle-treated animals. With a cutoff ANOVA p
value of 0.01, we identified 505 genes from ∼25,000 sequences. This set of 505
genes was analyzed using PCA, and prespecified genes of interest, such as SREBP
genes, fatty acid metabolism genes, and PXR genes, were extracted and clustered.
PCA, a method that allows one to determine the key variables that dis-
criminate the differences in the observations in a multidimensional data set, was
used to determine if RTV can be differentiated from the rest of the reference
compounds. PCA involves a set of linear transformations that converts a number
of correlated variables in gene expression profiles into a set of new variables
called principal components (PCs). PCs, orthogonal to each other, are taken
together to explain all the variance contained in the original data. The trans-
formations are defined in such a way that the projection of profiles onto key PCs
allows one to capture features of profiles. The linear combination of genes that
defines each PC is called PC loading. The projection of each profile onto PCs is
called PC score. The microarray data were also analyzed using the Rosetta
Resolver (Biosoft, Seattle, WA, USA) analysis program as well as in-house
custom bioinformatics tools.
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